Cargando…

Immune‐mediated thrombocytopenia induced with durvalumab after chemoradiotherapy in a non‐small cell lung cancer patient: A case report

We describe a case of a 60‐year‐old man with a prolonged thrombocytopenia during a durvalumab maintenance therapy after chemoradiotherapy for locally advanced non‐small cell lung carcinoma. Bone marrow specimen was normoplastic with the marked megakaryocyte depletion, which was assumed to be an acqu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Makiguchi, Tomonori, Tanaka, Hisashi, Kamata, Kosuke, Taima, Kageaki, Kurose, Akira, Tasaka, Sadatomo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2021
Materias:	Case Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8520809/ https://www.ncbi.nlm.nih.gov/pubmed/34405563 http://dx.doi.org/10.1111/1759-7714.14106

Ejemplares similares

Destroyed lung due to sustained inflammation after chemoradiotherapy followed by durvalumab
por: Taima, Kageaki, et al.
Publicado: (2020)

Safety and feasibility of carboplatin and paclitaxel in combination with nintedanib for non-small cell lung cancer patients with idiopathic pulmonary fibrosis: a prospective pilot study
por: Makiguchi, Tomonori, et al.
Publicado: (2023)

Diabetic ketoacidosis shortly after COVID‐19 vaccination in a non–small‐cell lung cancer patient receiving combination of PD‐1 and CTLA‐4 inhibitors: A case report
por: Makiguchi, Tomonori, et al.
Publicado: (2022)

Acute Exacerbation of Interstitial Lung Disease After SARS-CoV-2 Vaccination: A Case Series
por: Ishioka, Yoshiko, et al.
Publicado: (2022)

Activity and bioavailability of tepotinib for leptomeningeal metastasis of NSCLC with MET exon 14 skipping mutation
por: Tanaka, Hisashi, et al.
Publicado: (2021)

Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study
por: Ishioka, Yoshiko, et al.
Publicado: (2023)

Feasibility and safety of platinum-doublet therapy in patients with small-cell lung cancer in the third-line setting: A multi-institutional retrospective study
por: Fukushima, Takashi, et al.
Publicado: (2022)

Procalcitonin expression in patients with large cell neuroendocrine carcinoma of the lung
por: Itoga, Masamichi, et al.
Publicado: (2021)

Granulomatosis with Polyangiitis following COVID-19 in an Adolescent
por: Nakamura, Yume, et al.
Publicado: (2023)

Regression of Crizotinib-Associated Complex Cystic Lesions after Switching to Alectinib
por: Taima, Kageaki, et al.
Publicado: (2017)

Effect of nintedanib on non‐small cell lung cancer in a patient with idiopathic pulmonary fibrosis: A case report and literature review
por: Shiratori, Toshihiro, et al.
Publicado: (2020)

A phase I study of afatinib for patients aged 75 or older with advanced non-small cell lung cancer harboring EGFR mutations
por: Tanaka, Hisashi, et al.
Publicado: (2018)

Morphological features of bronchiectasis in patients with non-tuberculous mycobacteriosis and interstitial pneumonia
por: Tabe, Chiori, et al.
Publicado: (2022)

A pilot study of adjuvant chemotherapy with carboplatin and oral S‐1 for patients with completely resected stage II to IIIA non‐small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2020)

A single-arm phase II study of nab-paclitaxel for patients with chemorefractory non-small cell lung cancer
por: Tanaka, Hisashi, et al.
Publicado: (2017)

Efficacy of pembrolizumab for patients with both high PD‐L1 expression and an MET exon 14 skipping mutation: A case report
por: Baba, Keisuke, et al.
Publicado: (2019)

Emergency Radiotherapy for Spinal Cord Compression due to Bone Sarcoidosis
por: Tanaka, Yoshihito, et al.
Publicado: (2017)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Durvalumab/elasomeran: Immune thrombocytopenia: case report
Publicado: (2022)

The long-term survival of a thymic carcinoma patient treated with S-1: a case report and literature review
por: Tanaka, Hisashi, et al.
Publicado: (2013)

Drug‐induced immune‐mediated thrombocytopenia secondary to durvalumab use
por: Dougherty, Sean C., et al.
Publicado: (2021)

Prospective analysis of factors precluding the initiation of durvalumab from an interim analysis of a phase II trial of S-1 and cisplatin with concurrent thoracic radiotherapy followed by durvalumab for unresectable, locally advanced non-small cell lung cancer in Japan (SAMURAI study)
por: Tanzawa, Shigeru, et al.
Publicado: (2022)

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events
por: Miura, Yu, et al.
Publicado: (2020)

The efficacy of nintedanib in 158 patients with idiopathic pulmonary fibrosis in real-world settings: A multicenter retrospective study
por: Dobashi, Masaki, et al.
Publicado: (2021)

Asthma caused by durvalumab after chemoradiotherapy in two patients with non‐small cell lung cancer
por: Uemura, Takehiro, et al.
Publicado: (2021)

Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non‐small cell lung cancer prior to the approval of durvalumab
por: Fukui, Tomoya, et al.
Publicado: (2020)

Exploring causes and consequences of early discontinuation of durvalumab after chemoradiotherapy for non-small cell lung cancer
por: Pennock, Michael, et al.
Publicado: (2023)

Effect of durvalumab on local control after concurrent chemoradiotherapy for locally advanced non‐small cell lung cancer in comparison with chemoradiotherapy alone
por: Abe, Takanori, et al.
Publicado: (2020)

Predicting factors of symptomatic radiation pneumonitis induced by durvalumab following concurrent chemoradiotherapy in locally advanced non-small cell lung cancer
por: Mayahara, Hiroshi, et al.
Publicado: (2022)

Acquired amegakaryocytic thrombocytopenia after durvalumab administration
por: Suyama, Takahiro, et al.
Publicado: (2021)

Dramatic response to alectinib in a patient of ALK-rearranged lung cancer with poor performance status
por: Tanaka, Hisashi, et al.
Publicado: (2016)

Impact of radiation on host immune system in patients treated with chemoradiotherapy and durvalumab consolidation for unresectable locally advanced non-small cell lung cancer
por: Pasquier, Corentin, et al.
Publicado: (2023)

Rescue computed tomography-guided drainage of a giant mediastinal mature teratoma causing airway obstruction prior to surgical resection: a case report
por: Tani, Kengo, et al.
Publicado: (2023)

Durvalumab Consolidation Treatment after Chemoradiotherapy for an HIV-Positive Patient with Locally Advanced Non-Small Cell Lung Cancer
por: Kawai, Shoko, et al.
Publicado: (2020)

Real‐world experience of consolidation durvalumab after concurrent chemoradiotherapy in stage III non‐small cell lung cancer
por: Huang, Yiqing, et al.
Publicado: (2022)

Sepsis caused by Listeria monocytogenes during chemotherapy for small cell carcinoma of the thymus
por: Itoga, Masamichi, et al.
Publicado: (2015)

Durvalumab-Induced Secondary Pure Red Cell Aplasia Successfully Treated With Cyclosporin
por: Watanabe, Kageaki, et al.
Publicado: (2020)

Predictors of lung injury during durvalumab maintenance therapy following concurrent chemoradiotherapy in unresectable locally advanced non‐small cell lung carcinoma
por: Hirama, Nobuyuki, et al.
Publicado: (2023)

Impact of Lymphopenia Recovery After Chemoradiotherapy on Durvalumab Consolidation Therapy in Stage III NSCLC
por: Kuge, Tomoki, et al.
Publicado: (2023)

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer
por: Spigel, David R., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_haf3io93bjsbm6257s5ll7lack